Arena Pharmaceuticals Company Profile (NASDAQ:ARNA)

About Arena Pharmaceuticals

Arena Pharmaceuticals logoArena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that target G protein-coupled receptors (GPCRs). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management, and is being commercialized under the brand name, BELVIQ. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. APD334 is an orally available modulator of the sphingosine 1-phosphate subtype 1 (S1P1) receptor intended for the treatment of multiple sclerosis, psoriasis, inflammatory bowel diseases and rheumatoid arthritis. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases and an undisclosed orphan GPCR for central nervous system indication(s).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARNA
  • CUSIP: 04004710
Key Metrics:
  • Previous Close: $1.60
  • 50 Day Moving Average: $1.67
  • 200 Day Moving Average: $1.71
  • 52-Week Range: $1.30 - $2.99
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.24
  • P/E Growth: 0.23
  • Market Cap: $381.91M
  • Outstanding Shares: 243,256,000
  • Beta: -0.53
Additional Links:
Companies Related to Arena Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Arena Pharmaceuticals (NASDAQ:ARNA) (?)
Ratings Breakdown: 4 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $2.75 (75.16% upside)

Analysts' Ratings History for Arena Pharmaceuticals (NASDAQ:ARNA)
Show:
DateFirmActionRatingPrice TargetDetails
8/13/2016Needham & Company LLCReiterated RatingHoldView Rating Details
8/10/2016Jefferies GroupReiterated RatingBuyView Rating Details
8/8/2016JPMorgan Chase & Co.Reiterated RatingHoldView Rating Details
5/10/2016Wells Fargo & Co.Reiterated RatingHoldView Rating Details
3/2/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details
3/1/2016Royal Bank Of CanadaReiterated RatingSector Perform$2.00 -> $1.50View Rating Details
10/28/2015WallachBeth CapitalLower Price TargetBuy$6.00 -> $4.00View Rating Details
5/14/2015BMO Capital MarketsReiterated RatingMarket Perform$9.00View Rating Details
9/4/2014Credit Suisse Group AGInitiated CoverageUnderperformView Rating Details
(Data available from 8/31/2014 forward)

Earnings

Earnings History for Arena Pharmaceuticals (NASDAQ:ARNA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2016        
8/8/2016Q216($0.10)($0.11)$10.44 million$9.50 millionViewN/AView Earnings Details
5/9/2016Q116($0.10)($0.09)$9.02 million$9.80 millionViewN/AView Earnings Details
2/29/2016Q415($0.13)($0.13)$8.26 million$7.80 millionViewN/AView Earnings Details
11/10/2015Q315($0.13)($0.11)$8.87 million$9.10 millionViewN/AView Earnings Details
8/5/2015Q215($0.14)($0.11)$10.95 million$9.18 millionViewN/AView Earnings Details
5/11/2015Q115($0.14)($0.10)$10.56 million$12.30 millionViewN/AView Earnings Details
3/2/2015Q414($0.12)($0.15)$10.36 million$9.20 millionViewN/AView Earnings Details
11/3/2014Q314($0.12)($0.05)$10.90 million$8.20 millionViewN/AView Earnings Details
8/1/2014Q2 14($0.11)$0.03$9.81 million$12.80 millionViewN/AView Earnings Details
5/12/2014Q114($0.10)($0.12)$7.98 million$6.80 millionViewN/AView Earnings Details
2/27/2014Q413$0.02($0.11)$7.00 million$6.50 millionViewN/AView Earnings Details
11/7/2013Q313($0.12)($0.08)$5.30 million$3.60 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.15$0.18$57.30 million$68.90 millionViewN/AView Earnings Details
4/30/2013Q1 2013$0.11$0.09$50.36 million$2.37 millionViewN/AView Earnings Details
3/4/2013Q4 2012($0.03)($0.10)$21.94 million$1.94 millionViewN/AView Earnings Details
11/6/2012Q312($0.11)($0.07)$3.72 million$1.50 millionViewN/AView Earnings Details
8/9/2012($0.08)($0.12)ViewN/AView Earnings Details
11/9/2011($0.14)($0.16)ViewN/AView Earnings Details
8/9/2011($0.15)($0.16)ViewN/AView Earnings Details
5/10/2011($0.21)($0.35)ViewN/AView Earnings Details
3/11/2011($0.22)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Arena Pharmaceuticals (NASDAQ:ARNA)
Current Year EPS Consensus Estimate: $-0.37 EPS
Next Year EPS Consensus Estimate: $-0.37 EPS

Dividends

Dividend History for Arena Pharmaceuticals (NASDAQ:ARNA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Arena Pharmaceuticals (NASDAQ:ARNA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/13/2016Christine Anna WhiteDirectorSell18,728$1.99$37,268.72View SEC Filing  
3/30/2015Randall E WoodsDirectorSell76,268$4.49$342,443.32View SEC Filing  
3/17/2015Steven W SpectorEVPSell70,000$5.00$350,000.00View SEC Filing  
1/8/2015Steven W SpectorEVPSell45,000$6.26$281,700.00View SEC Filing  
1/7/2015William R Shanahan JrSVPSell50,000$5.49$274,500.00View SEC Filing  
7/1/2014Jack LiefCEOSell223,525$5.85$1,307,621.25View SEC Filing  
6/27/2014Donald D BelcherDirectorSell2,473$5.85$14,467.05View SEC Filing  
5/6/2014Donald BelcherDirectorSell4,176$7.00$29,232.00View SEC Filing  
4/22/2014Harry Hixson, Jr.DirectorSell36,900$6.31$232,839.00View SEC Filing  
4/14/2014Tina Susan NovaDirectorSell35,000$6.22$217,700.00View SEC Filing  
4/1/2014Donald BelcherDirectorSell1,905$6.45$12,287.25View SEC Filing  
4/1/2014William Shanahan, Jr.SVPSell60,000$6.37$382,200.00View SEC Filing  
3/4/2014Steven SpectorEVPSell25,000$7.01$175,250.00View SEC Filing  
1/17/2014Jack LiefCEOSell100,000$7.81$781,000.00View SEC Filing  
1/10/2014Dominic BehanEVPSell33,332$6.25$208,325.00View SEC Filing  
9/10/2013Dominic P BehanEVPSell200,000$6.31$1,262,000.00View SEC Filing  
9/5/2013Steven W SpectorEVPSell20,000$6.54$130,800.00View SEC Filing  
5/21/2013Craig Michael AudetSVPSell83,750$8.00$670,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Arena Pharmaceuticals (NASDAQ:ARNA)
DateHeadline
News IconZeroing Our Focus on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Duncan Research (NASDAQ:ARNA)
www.duncanindependent.com - August 30 at 3:34 PM
News IconActive biotech company shares in the news: Raptor Pharmaceuticals ... - The Voice Registrar (NASDAQ:ARNA)
voiceregistrar.com - August 30 at 3:34 PM
uk.finance.yahoo.com logoWith Revenues Climbing, Innovus Pharma Adds Robert E. Hoffman as its Chief Financial Officer (NASDAQ:ARNA)
uk.finance.yahoo.com - August 29 at 8:21 AM
rttnews.com logoInnovus Pharma Appoints Robert Hoffman As EVP And CFO (NASDAQ:ARNA)
www.rttnews.com - August 29 at 8:21 AM
publicnow.com logoAug 29, 2016With Revenues Climbing, Innovus Pharma Adds Robert E. Hoffman as its Chief Financial Officer (NASDAQ:ARNA)
www.publicnow.com - August 29 at 8:21 AM
biz.yahoo.com logoARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events (NASDAQ:ARNA)
biz.yahoo.com - August 25 at 8:22 AM
capitalcube.com logoETF’s with exposure to Arena Pharmaceuticals, Inc. : August 23, 2016 (NASDAQ:ARNA)
www.capitalcube.com - August 23 at 3:37 PM
News IconARNA April 2017 Options Begin Trading (NASDAQ:ARNA)
www.stockoptionschannel.com - August 23 at 7:26 AM
News IconLet's Take a Closer Look at Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Duncan Research (NASDAQ:ARNA)
www.duncanindependent.com - August 22 at 3:36 PM
News IconSmall Cap Insight on Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Duncan Research (NASDAQ:ARNA)
www.duncanindependent.com - August 20 at 3:37 PM
finance.yahoo.com logoARENA PHARMACEUTICALS INC Financials (NASDAQ:ARNA)
finance.yahoo.com - August 18 at 3:44 PM
biz.yahoo.com logoARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:ARNA)
biz.yahoo.com - August 15 at 9:06 PM
streetinsider.com logoArena Pharma (ARNA) Appoints New Business Chief - StreetInsider.com (NASDAQ:ARNA)
www.streetinsider.com - August 15 at 3:39 PM
publicnow.com logoArena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer (NASDAQ:ARNA)
www.publicnow.com - August 15 at 10:48 AM
capitalcube.com logoETF’s with exposure to Arena Pharmaceuticals, Inc. : August 11, 2016 (NASDAQ:ARNA)
www.capitalcube.com - August 11 at 12:50 PM
seekingalpha.com logoArena: New Direction After $27 Million Loss? - Seeking Alpha (NASDAQ:ARNA)
seekingalpha.com - August 10 at 10:03 PM
smarteranalyst.com logoNeedham Remains Sidelined on Arena Pharmaceuticals, Inc. (ARNA) Following Quarterly Corporate Update - Smarter Analyst (NASDAQ:ARNA)
www.smarteranalyst.com - August 10 at 10:03 PM
capitalcube.com logoArena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:ARNA)
www.capitalcube.com - August 10 at 3:57 PM
4-traders.com logoArena Pharmaceuticals : reports 2Q loss (NASDAQ:ARNA)
www.4-traders.com - August 9 at 10:11 PM
seekingalpha.com logoArena Pharmaceuticals' (ARNA) CEO Amit Munshi on Q2 2016 Results - Earnings Call Transcript (NASDAQ:ARNA)
seekingalpha.com - August 9 at 4:41 PM
investopedia.com logoWhat to Expect in Arena Pharmaceuticals Earnings (ARNA) - Investopedia (NASDAQ:ARNA)
www.investopedia.com - August 9 at 12:24 PM
investopedia.com logoWhat to Expect in Arena Pharmaceuticals Earnings (ARNA) (NASDAQ:ARNA)
www.investopedia.com - August 8 at 9:02 PM
smarteranalyst.com logoStock Update (NASDAQ:ARNA): Arena Pharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:ARNA)
www.smarteranalyst.com - August 8 at 9:02 PM
sg.finance.yahoo.com logoArena Pharmaceuticals reports 2Q loss (NASDAQ:ARNA)
sg.finance.yahoo.com - August 8 at 9:02 PM
thestreet.com logoHow Will Arena Pharmaceuticals (ARNA) Stock React to Q2 Miss? (NASDAQ:ARNA)
www.thestreet.com - August 8 at 9:02 PM
investopedia.com logoWhat to Expect in Arena Pharmaceuticals Earnings? (NASDAQ:ARNA)
www.investopedia.com - August 8 at 3:37 PM
News IconAnalyst's Estimates: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Post Registrar (NASDAQ:ARNA)
postregistrar.com - August 8 at 8:22 AM
biz.yahoo.com logoQ2 2016 Arena Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:ARNA)
biz.yahoo.com - August 8 at 8:22 AM
equities.com logoArena Pharmaceuticals Inc. (ARNA) Jumps 6.14% on August 03 - Equities.com (NASDAQ:ARNA)
www.equities.com - August 3 at 9:15 PM
publicnow.com logoArena Pharmaceuticals to Release Second Quarter 2016 Financial Results and Provide Corporate Update on Monday, August 8, 2016 (NASDAQ:ARNA)
www.publicnow.com - August 2 at 8:23 AM
zacks.com logoArena (ARNA) Q2 Earnings: What's in Store for the Stock? (NASDAQ:ARNA)
www.zacks.com - August 1 at 8:30 AM
News IconTop Earnings to Watch for: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - The Voice Registrar (NASDAQ:ARNA)
voiceregistrar.com - July 30 at 3:39 PM
News IconBiotech Stocks Worth a Closer Look: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Merrimack Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:ARNA)
voiceregistrar.com - July 28 at 12:19 PM
streetupdates.com logoAnalyst's Stocks Ratings Trend: GlaxoSmithKline PLC (NYSE:GSK) , Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Street Updates (NASDAQ:ARNA)
www.streetupdates.com - July 28 at 12:19 PM
4-traders.com logoArena Pharmaceuticals : Eisai Inc. and Arena Pharmaceuticals Announce FDA Approval of BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets (NASDAQ:ARNA)
www.4-traders.com - July 27 at 9:20 PM
fortune.com logoThe Insider Activity Don't Lie: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Review Fortune (NASDAQ:ARNA)
reviewfortune.com - July 27 at 3:35 PM
fortune.com logoLatest Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Target Price Suggests Stock Is Worth $3.75/Share - Review Fortune (NASDAQ:ARNA)
reviewfortune.com - July 26 at 1:12 PM
capitalcube.com logoETF’s with exposure to Arena Pharmaceuticals, Inc. : July 26, 2016 (NASDAQ:ARNA)
www.capitalcube.com - July 26 at 11:42 AM
News IconArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Receives FDA’s Approval Of BELVIX XR CIV. (NASDAQ:ARNA)
wallstreetpr.com - July 25 at 4:07 PM
News IconArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Receives FDA’s Approval Of BELVIX XR CIV. (NASDAQ:ARNA)
wallstreetpr.com - July 25 at 4:07 PM
streetupdates.com logoTwo Stocks within Analysts Review: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) , Zimmer Biomet Holdings, Inc ... - Street Updates (NASDAQ:ARNA)
www.streetupdates.com - July 25 at 8:22 AM
News IconStock Displaying Signs of a Downtrend: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Press Telegraph (NASDAQ:ARNA)
presstelegraph.com - July 23 at 3:33 PM
News IconEquity Roundup: Stock Performance Focus on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Press Telegraph (NASDAQ:ARNA)
presstelegraph.com - July 23 at 6:37 AM
streetupdates.com logoTwo Stocks to Watch: OpGen, Inc. (NASDAQ:OPGN) , Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Street Updates (NASDAQ:ARNA)
www.streetupdates.com - July 22 at 3:33 PM
fortune.com logoWhich way Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) insiders are heading - Review Fortune (NASDAQ:ARNA)
reviewfortune.com - July 21 at 3:36 PM
News IconStock Performance to Track: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - News Oracle (NASDAQ:ARNA)
www.newsoracle.com - July 21 at 3:36 PM
capitalcube.com logoArena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : July 21, 2016 (NASDAQ:ARNA)
www.capitalcube.com - July 21 at 8:17 AM
streetupdates.com logoTwo Stocks within Analysts Limelight: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) , Calithera Biosciences, Inc ... - Street Updates (NASDAQ:ARNA)
www.streetupdates.com - July 20 at 11:02 PM
equities.com logoArena Pharmaceuticals Inc. (ARNA) is Trading Higher on Unusual Volume for July 19 - Equities.com (NASDAQ:ARNA)
www.equities.com - July 20 at 11:02 PM
nasdaq.com logoSCLN Withdraws From Auction Block, ZFGN Tumbles, Double Blessing For VRX (NASDAQ:ARNA)
www.nasdaq.com - July 20 at 4:47 PM

Social

Arena Pharmaceuticals (NASDAQ:ARNA) Chart for Wednesday, August, 31, 2016


Last Updated on 8/31/2016 by MarketBeat.com Staff